Study of combination immunosuppressive therapy in primary sclerosing cholangitis - A multicenter study for combination immunosuppressive therapy with mizoribine and azathioprine -

Study of combination immunosuppressive therapy in primary sclerosing cholangitis - A multicenter study for combination immunosuppressive therapy with mizoribine and azathioprine - - Study of combination immunosuppressive therapy in primary sclerosing cholangitis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029482

Enrollment

Registered

2017-10-10

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary sclerosing cholangitis

Interventions

Administration of mizoribine and azathioprine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with primary sclerosing cholangitis 2. Patients given written informed consent

Exclusion criteria

Exclusion criteria: 1. Patients with some history of hypersensitivity to Bredini, Imuran, or Azanin Tablets 2. WBC:<=3000/mm3 3. Pregnants or patients who desire pregnancy 4. Patients with severe allergy 5. Patients who are judged inappropriate by the principal investigator

Design outcomes

Primary

Measure	Time frame
Liver function (AST, ALT or gamma GTP, jaundice)	—

Secondary

Measure	Time frame
1.Hepatic histopathological evaluation 2.MRCP 3.Physical conditions 4.Incidence of adverse event and abnormal laboratory data	—

Countries

Japan

Contacts

Public ContactHitoshi Tajiri

Osaka General Medical Center Department of Pediatrics

tajiriji@gh.opho.jp06-6692-1201

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026